Morgan Stanley’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-231,428
| Closed | -$81K | – | 6717 |
|
|
2016
Q3 | $81K | Sell |
231,428
-24,869
| -10% | -$8.7K | ﹤0.01% | 5396 |
|
|
2016
Q2 | $119K | Sell |
256,297
-84,740
| -25% | -$39.3K | ﹤0.01% | 5175 |
|
|
2016
Q1 | $464K | Buy |
341,037
+82,992
| +32% | +$113K | ﹤0.01% | 4496 |
|
|
2015
Q4 | $380K | Sell |
258,045
-143,803
| -36% | -$212K | ﹤0.01% | 4721 |
|
|
2015
Q3 | $634K | Sell |
401,848
-63,552
| -14% | -$100K | ﹤0.01% | 4456 |
|
|
2015
Q2 | $792K | Buy |
465,400
+100,250
| +27% | +$171K | ﹤0.01% | 4375 |
|
|
2015
Q1 | $507K | Sell |
365,150
-12,006
| -3% | -$16.7K | ﹤0.01% | 4646 |
|
|
2014
Q4 | $569K | Sell |
377,156
-74,900
| -17% | -$113K | ﹤0.01% | 4575 |
|
|
2014
Q3 | $932K | Buy |
452,056
+147,913
| +49% | +$305K | ﹤0.01% | 4093 |
|
|
2014
Q2 | $930K | Sell |
304,143
-139,120
| -31% | -$425K | ﹤0.01% | 4115 |
|
|
2014
Q1 | $1.11M | Sell |
443,263
-42,154
| -9% | -$105K | ﹤0.01% | 3900 |
|
|
2013
Q4 | $2.41M | Buy |
485,417
+213,769
| +79% | +$1.06M | ﹤0.01% | 3248 |
|
|
2013
Q3 | $620K | Sell |
271,648
-419,133
| -61% | -$957K | ﹤0.01% | 4185 |
|
|
2013
Q2 | $1.53M | Buy |
+690,781
| New | +$1.53M | ﹤0.01% | 3363 |
|
Morgan Stanley's RXII Position: Q4 2016 in Review
Morgan Stanley sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 231,428 shares — an estimated $81K sold.
Morgan Stanley first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $2.41M in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- Morgan Stanley reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- Morgan Stanley sold 231,428 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $81K.
- Morgan Stanley first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
- Morgan Stanley's GALENA BIOPHARMA INC COM position peaked at $2.41M in Q4 2013.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on Morgan Stanley's 13F filing for Q4 2016, filed 13 Feb 2017.